Icon secures full ownership of medical imaging firm
This article was originally published in Clinica
Executive Summary
Icon, a provider of outsourced development services in the medtech sector, has gained full ownership of its medical imaging division Icon Medical Imaging. The deal sees Icon secure the outstanding 30% stake of the subsidiary for an undisclosed fee. Dublin, Ireland-based Icon had previously purchased a 70% stake in the firm in 2004, when it was known by its original name Beacon Biosciences. Beacon subsequently changed its name to Icon Medical Imaging in 2007.The division provides pharmaceutical, biotech and life science clients with laboratory imaging services and, according to Icon, has managed more than 260 imaging trials in oncology, cardiovascular, central nervous system, medical devices and imaging agents.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals